- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare Mirae Asset Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹99 | ₹100 |
Expense Ratio | 1.96 | 1.94 |
NAV | ₹36.67 | ₹37.55 |
Fund Started | 11 Jun 2018 | 25 Jun 2018 |
Fund Size | ₹2667.40 Cr | ₹4914.64 Cr |
Exit Load | Exit load of 1% if redeemed within 1 year. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
2.0
4.0
Min SIP Amount
₹99
₹100
Expense Ratio
1.96
1.94
NAV
₹36.67
₹37.55
Fund Started
11 Jun 2018
25 Jun 2018
Fund Size
₹2667.40 Cr
₹4914.64 Cr
Exit Load
Exit load of 1% if redeemed within 1 year.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 18.06% | 21.86% |
3 Year | 18.53% | 24.24% |
5 Year | 22.36% | 25.16% |
1 Year
18.06%
21.86%
3 Year
18.53%
24.24%
5 Year
22.36%
25.16%
Holding Analysis
Equity | 99.55% | 98.28% |
Cash | 0.45% | 1.72% |
Equity
99.55%
98.28%
Cash
0.45%
1.72%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.90% |
Aurobindo Pharma Ltd. | 7.12% |
Cipla Ltd. | 6.91% |
Divi's Laboratories Ltd. | 6.60% |
Lupin Ltd. | 6.20% |
Glenmark Pharmaceuticals Ltd. | 5.86% |
Apollo Hospitals Enterprise Ltd. | 5.48% |
Dr. Reddy's Laboratories Ltd. | 4.15% |
Krishna Institute of Medical Sciences Ltd | 4.13% |
Suven Pharmaceuticals Ltd. | 3.95% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.50% |
Dr. Reddy's Laboratories Ltd. | 8.95% |
Cipla Ltd. | 8.85% |
Divi's Laboratories Ltd. | 6.71% |
Aurobindo Pharma Ltd. | 5.30% |
Lupin Ltd. | 4.73% |
Alkem Laboratories Ltd. | 4.42% |
Mankind Pharma Ltd. | 3.50% |
Gland Pharma Ltd. | 3.39% |
Zydus Lifesciences Ltd. | 3.10% |
Fund Manager
Name | Vrijesh Kasera | Dharmesh Kakkad |
Start Date | 03 Feb 2023 | 23 Feb 2021 |
Name
Vrijesh Kasera
Dharmesh Kakkad
Start Date
03 Feb 2023
23 Feb 2021
About Fund
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 11 Jun 2018 | 25 Jun 2018 |
Description
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
11 Jun 2018
25 Jun 2018